NCT04319198 2025-09-30
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
Phase 4 Completed
Clinical Trials
3 trialsNCT03523390 2024-02-23
Phase I/Ib Multiple Ascending Dose Study in China
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03573544 2024-02-22
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
OBI Pharma, Inc
Phase 1/2 Terminated